These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19277451)

  • 1. Treatment of hepatitis C in hemodialysis patients using pegylated interferon alpha-2a in Turkey.
    Kose S; Gurkan A; Akman F; Kelesoglu M; Uner U
    J Gastroenterol; 2009; 44(4):353-8. PubMed ID: 19277451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C.
    Köse Ş; Senger SS; Ersan G; Çavdar G
    Clin Exp Nephrol; 2013 Feb; 17(1):115-9. PubMed ID: 22814955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
    Alsaran K; Sabry A; Shaheen N
    Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.
    Akhan SC; Kalender B; Ruzgar M
    Infection; 2008 Aug; 36(4):341-4. PubMed ID: 18629437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow up of sustained viral response after treatment of hepatitis C with pegylated interferon alpha-2a in hemodialysis patients.
    Dzekova P; Asani A; Selim G; Gelev S; Trajceska L; Amitov V; Selja N; Zabzun M; Mena S; Gaseva M; Sikole A
    Int J Artif Organs; 2009 Mar; 32(3):180-4. PubMed ID: 19440994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
    Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T
    Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection.
    Chan TM; Ho SK; Tang CS; Tse KC; Lam MF; Lai KN; Yung S
    Nephrology (Carlton); 2007 Feb; 12(1):11-7. PubMed ID: 17295655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis.
    Goel A; Bhadauria DS; Kaul A; Prasad N; Gupta A; Sharma RK; Rai P; Aggarwal R
    Nephrology (Carlton); 2017 Sep; 22(9):706-711. PubMed ID: 27286895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study.
    Tsubota A; Satoh K; Aizawa M; Takamatsu S; Namiki Y; Ohkusa T; Fujise K; Tajiri H
    World J Gastroenterol; 2008 Dec; 14(47):7220-4. PubMed ID: 19084937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
    Dogan UB; Atabay A; Akin MS; Yalaki S
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1082-5. PubMed ID: 23524524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
    Kokoglu OF; Uçmak H; Hosoglu S; Cetinkaya A; Kantarceken B; Buyukbese MA; Isik IO
    J Gastroenterol Hepatol; 2006 Mar; 21(3):575-80. PubMed ID: 16638102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Pegylated Interferon Alpha-2b Monotherapy in Hepatitis C Virus-Infected Children with End-Stage Renal Disease on Hemodialysis.
    Mogahed EA; Abdelaziz H; Helmy H; Ghita H; Abdel Mawla MA; Hassanin F; Fadel FI; El-Karaksy H
    J Interferon Cytokine Res; 2016 Dec; 36(12):681-688. PubMed ID: 27656950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C.
    Yada M; Masumoto A; Yamashita N; Motomura K; Koyanagi T; Sakamoto S
    World J Gastroenterol; 2010 Mar; 16(12):1506-11. PubMed ID: 20333792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy.
    Sikole A; Dzekova P; Selja N; Gaseva M; Nikolov IG; Zabzun M; Muharemi S; Asani A; Amitov V; Mena S; Grunevska V; Ivanovski L; Polenakovic M
    Ren Fail; 2007; 29(8):961-6. PubMed ID: 18067041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit.
    Covic A; Maftei ID; Mardare NG; Ioniţă-Radu F; Totolici C; Tuţă L; Golea O; Covic M; Volovăţ C; Gusbeth-Tatomir P; Mircescu G
    J Nephrol; 2006; 19(6):794-801. PubMed ID: 17173254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of chronic hepatitis C virus infection in hemodialysis patients].
    Kaya S
    Mikrobiyol Bul; 2008 Jul; 42(3):525-34. PubMed ID: 18822900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis.
    Casanovas-Taltavull T; Baliellas C; Llobet M; Cruzado JM; Castellote J; Casanova A; Niubó J; Valls C; Serrano T
    Transplant Proc; 2007 Sep; 39(7):2125-7. PubMed ID: 17889113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.